Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical… Read More
PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology By Dr John Comley The prospect of enabling higher throughput electro-physiology (patch-clamping) has created much expectation from scientists within the ion channel community. Yet there are opposing views among traditional electro-physiologists and screeners as to the needed specification and… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease… Read More
Global Dealmaking (part 1) – The Pitch By Dr Paul Charlton The age-old adage that your product is only as good as the person selling it still holds true in today’s highly competitive pharmaceutical environment. Yet basic presentation skills are, in many cases, somewhat lacking. This article, the… Read More
The Industrial Evolution of Screening Infrastructure By Chris Molloy Industrialisation of screening depends upon the use of a stable,mature infrastructure. According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market. Read More
The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components,… Read More
New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a… Read More
The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will… Read More
TRANSCRIPTOMICS – Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug… Read More
The transition from scientist to business manager in a biotech/drug discovery start-up By Dr Paul Charlton The move from a successful scientific career into senior management of a high technology start-up company frequently presents a paradigm shift for the individual in the way that they must manage both… Read More
Finding and minding R&D talent the hidden human cost of merger mania By Sue Harris This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining… Read More
CNS Drug Discovery – Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Read More
Proteomatics – New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Read More
The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well… Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and… Read More
Monoclonal Antibodies – Magic bullets or a shot in the dark By Dr Fiona Adair It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in… Read More